Mouse monoclonal antibody to Amyloid beta peptide (A-beta 40/42), [MOAB-2] - Biotinylated
DescriptionThe amyloid beta peptide is derived from the cleavage of the Amyloid precursor protein (APP) and varies in length from 39 to 43 amino acids. However, the form(s) of amyloid-beta peptide (Aß) associated with the pathology characteristic of Alzheimer€™s disease (AD) remains unclear. In particular, the neurotoxicity of intraneuronal Aß accumulation is an area of considerable research and controversy principally because antibodies thought to be specific for Aß have been shown to actually detect intraneuronal APP and not Aß exclusively.
MOAB-2 (mouse IgG2b) is a pan-specific, high-titer antibody to Aß residues 1-4 as demonstrated by biochemical and immunohistochemical analyses (IHC), and is highly specific just to amyloid beta peptide. MOAB-2 did not detect APP or APP-CTFs in cell culture media/lysates (HEK-APPSwe or HEK APPSwe/BACE1) or in brain homogenates from transgenic mice expressing 5 familial AD (FAD) mutation (5xFAD mice).
Using IHC on 5xFAD brain tissue, MOAB-2 immunoreactivity co-localized with C-terminal antibodies specific for Aß40 and Aß42. MOAB-2 did not co-localize with either N- or C-terminal antibodies to APP. In addition, no MOAB-2-immunreactivity was observed in the brains of 5xFAD/BACE-/- mice, although significant amounts of APP were detected by N- and C-terminal antibodies to APP, as well as by 6E10. In both 5xFAD and 3xTg mouse brain tissue, MOAB-2 co-localized with cathepsin-D, a marker for acidic organelles, further evidence for intraneuronal Aß, distinct from Aß associated with the cell membrane. MOAB-2 demonstrated strong intraneuronal and extra-cellular immunoreactivity in 5xFAD and 3xTg mouse brain tissues.
Biosensis now offers biotinylated MOAB-2 antibody allowing more flexibility in experimental design by using the biotin-avidin/streptavidin detection method. Biotinylated MOAB-2 antibody may also help to reduce background staining in difficult-to-stain tissues and increase detection sensitivity. The ability of biotinylated MOAB-2 antibody to detect amyloid beta has been validated by IHC.
Purified, non-biotinylated MOAB-2 antibody is available .
Labviva Id: LV-0358-0020
|Attribute Type||Attribute Value|
|Product Size||50 µg|
|Uniprot Full Accession Number & Name||P05067 A4_HUMAN|
|Expiry Date||12 months after purchase.|
|Shipping Temperature||25°C (Ambient)|
|Product Specificity||MOAB-2 detects preparations enriched in U-, O-, F-Aß42, and U-Aß40 by dot-blot, and is thus a pan-specific Aß antibody. However, MOAB-2 is selective for the more neurotoxic Aß42 compared to Aß40. Indeed, MOAB-2 demonstrated a titration against antigen con|
|Uniprot Number only||P05067|
|Purity||Antibody was purified from cell culture supernatant by Protein G chromatography, biotinylated and buffer-exchanged into PBS, pH 7.4 buffer|
|Alternative Name||Beta-APP42; Beta-APP40; Beta-amyloid protein 42; Beta-amyloid protein 40; ABPP; APPI; Amyloid beta A4 protein; MOAB2; MOAB-2; Alzheimer's antibody; AB40; AB42; abeta|
|Storage||After reconstitution keep aliquots at -20 °C to -70 °C for a higher stability. At 2-8 °C keep up to one week; use sterile methods and pipettes. Highly purified glycerol (1:1) may be added for an additional stability. Avoid repetitive freeze/thaw cycles. K|
|Immunogen||Recombinant human amyloid beta protein 42 (Aß42): DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA|
|Reconstitution||Spin vial briefly before opening. Reconstitute in 50 µL of sterile water to give a concentration of 1 mg/mL. Centrifuge to remove any insoluble material. Final buffer is PBS, pH 7.4 without preservative.|
Purified, non-biotinylated MOAB-2 antibody, cat# M-1586-100
Oligomeric Aß ELISA Kit, cat# BEK-2215-1P/2P
|Format||contains no preservative., Lyophilized from PBS buffer, pH 7.4|
|Applications||ELISA, IMMUNOHISTOCHEMISTRY, IMMUNOPRECIPITATION, WESTERN BLOTTING|
|Species reactivity||HUMAN, RODENT|
|PRODUCTNAME||Mouse monoclonal antibody to Amyloid beta peptide (A-beta 40/42), [MOAB-2] - Biotinylated|
Protocols & Papers
Ruan CS; Liu J; Yang M; Saadipour K; Zeng YQ; Liao H; Wang YJ; Bobrovskaya L; Zhou XF
Experimental neurology.; Volume 299, Issue Pt A 2018/01/01
ER-associated degradation regulates Alzheimer's amyloid pathology and memory function by modulating ?-secretase activity.
Zhu B; Jiang L; Huang T; Zhao Y; Liu T; Zhong Y; Li X; Campos A; Pomeroy K; Masliah E; Zhang D; Xu H
Nature communications.; Volume 8, Issue 1 2017/11/13
Huang TY; Zhao Y; Jiang LL; Li X; Liu Y; Sun Y; Piña-Crespo JC; Zhu B; Masliah E; Willnow TE; Pasquale EB; Xu H
The Journal of experimental medicine.; Volume 214, Issue 12 2017/12/04
Peripheral Inflammation, Apolipoprotein E4, and Amyloid-ß Interact to Induce Cognitive and Cerebrovascular Dysfunction.
Marottoli FM; Katsumata Y; Koster KP; Thomas R; Fardo DW; Tai LM
ASN neuro.; Volume 9, Issue 4 2017 Jul-Aug
Epidermal growth factor prevents APOE4 and amyloid-beta-induced cognitive and cerebrovascular deficits in female mice.
Thomas R; Zuchowska P; Morris AW; Marottoli FM; Sunny S; Deaton R; Gann PH; Tai LM
Acta neuropathologica communications.; Volume 4, Issue 1 2016/10/27
Kim YH; Choi SH; D'Avanzo C; Hebisch M; Sliwinski C; Bylykbashi E; Washicosky KJ; Klee JB; Brüstle O; Tanzi RE; Kim DY
Nature protocols.; Volume 10, Issue 7 2015/07/01
Microglia constitute a barrier that prevents neurotoxic protofibrillar Aß42 hotspots around plaques.
Condello C; Yuan P; Schain A; Grutzendler J
Nature communications.; Volume 6, Issue 2015/01/29
Intracellular Aß pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study.
Iulita MF; Allard S; Richter L; Munter LM; Ducatenzeiler A; Weise C; Do Carmo S; Klein WL; Multhaup G; Cuello AC
Acta neuropathologica communications.; Volume 2, Issue 2014/06/05
Smith BR; Santos MB; Marshall MS; Cantuti-Castelvetri L; Lopez-Rosas A; Li G; van Breemen R; Claycomb KI; Gallea JI; Celej MS; Crocker SJ; Givogri MI; Bongarzone ER
The Journal of pathology.; Volume 232, Issue 5 2014/04/01